Long-term survival with respect to LEF1 expression
| Clinical outcome . | LEF1 low . | LEF1 high . | P . |
|---|---|---|---|
| RFS, relapse-free at 5 y, % (95% CI) | |||
| Overall cohort (N = 230) | 47 (35-59) | 27 (8-47) | .05 |
| Standard-risk (N = 85) | 57 (43-71) | 36 (12-61) | .02 |
| OS, alive at 5 y, % (95% CI) | |||
| Overall cohort (N = 282) | 47 (38-56) | 29 (14-44) | .06 |
| Standard-risk (N = 91) | 72 (60-84) | 53 (29-77) | .08 |
| Standard-risk, age > 35 y (N = 41) | 63 (44-82) | 27 (12-42) | .02 |
| Clinical outcome . | LEF1 low . | LEF1 high . | P . |
|---|---|---|---|
| RFS, relapse-free at 5 y, % (95% CI) | |||
| Overall cohort (N = 230) | 47 (35-59) | 27 (8-47) | .05 |
| Standard-risk (N = 85) | 57 (43-71) | 36 (12-61) | .02 |
| OS, alive at 5 y, % (95% CI) | |||
| Overall cohort (N = 282) | 47 (38-56) | 29 (14-44) | .06 |
| Standard-risk (N = 91) | 72 (60-84) | 53 (29-77) | .08 |
| Standard-risk, age > 35 y (N = 41) | 63 (44-82) | 27 (12-42) | .02 |
Patients who received SCT in CR1 were censored at the time of transplantation.